Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $933.77M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 2.87M
Average 2.58M
VSTM EBITDA Margin
EBITDA as a percentage of revenue.
Verastem, Inc.NASDAQ: VSTM
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin at -192.4%
EBITDA Margin was -192.4% in Q1 FY2026. On a trailing-twelve-month basis it was -387.1%, up 1063.3 pp year over year. Over 3 fiscal years it widened by 2084.9 pp.
Context
- EBITDA Margin widened in 2 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -125.1% for the fiscal year ending Dec 2026, up from -671.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -192.4%-8.8 pp QoQ
- Last fiscal yearDec 2025
- -671.6%+587.1 pp YoY
- LTMMar 2026
- -387.1%+1063.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +1010.0 pp | — |
| 1 year | +587.1 pp | +546.5 pp | -40.6 pp |
| 3 years | +2084.9 pp | +625.6 pp | -1459.3 pp |
| 5 years | +670.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -671.6%
- Year-over-year change
- +587.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -671.6% | +587.1pp |
| FY2024 | 2024-12-31 | -1258.6% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | -2756.4% | +222.4pp |
| FY2021 | 2021-12-31 | -2978.9% | — |
EBITDA Margin vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 EBITDA Margin of -387.1% is the 4th highest of the 7 companies compared; the peer median is -371.6%.
- Its year-over-year change of +1063.3 pp is the 3rd highest of 6, against a peer median of +77.3 pp.
- Over three fiscal years its change of +2084.9 pp compares with a peer median of +319.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -74.8% | +1326.6 pp | — | |
| LTM Mar 2026 | -257.0% | +77.3 pp | +319.4 pp | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| LTM Mar 2026 | -387.1% | +1063.3 pp | +2084.9 pp | |
| LTM Mar 2026 | -455.3% | +1345.3 pp | — | |
| LTM Jun 2024 | -979.5% | — | — | |
| LTM Mar 2026 | -8329.5% | -111.2 pp | +2386.2 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | FY2025 | — | — | — |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding VSTM) | -371.6% | +77.3 pp | +319.4 pp | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.6M | 0 | 10M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.3M |
| Gross Profit | 2.05M | 2.6M | 0 | 10M | 25.62M |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 82.9% |
| Research & Development | 39.35M | 50.56M | 61.36M | 81.33M | 114.6M |
| Selling, General & Admin | 24.12M | 24.98M | 30.73M | 43.62M | 81.15M |
| Operating Expenses | 63.46M | 75.53M | 92.08M | 124.96M | 195.75M |
| Depreciation & Amortization | 72K | 118K | 62K | 26K | 728K |
| EBITDA | (61.16M) | (71.56M) | (83.17M) | (125.86M) | (207.61M) |
| EBITDA Margin | -2978.9% | -2756.4% | — | -1258.6% | -671.6% |
| Operating Income | (61.41M) | (72.94M) | (92.08M) | (114.96M) | (170.13M) |
| Operating Margin | -2991.2% | -2809.6% | — | -1149.6% | -550.3% |
| Interest Income | 181K | 1.22M | 6.21M | 4.15M | 4.07M |
| Interest Expense | 9.97M | 2.14M | 4.14M | 4.56M | 1.14M |
| Other Income / Expenses | (9.79M) | (875K) | 4.72M | (15.5M) | (39.34M) |
| Income Before Tax | (71.2M) | (73.81M) | (87.37M) | (130.45M) | (209.47M) |
| Pre-Tax Margin | -3468.1% | -2843.3% | — | -1304.5% | -677.6% |
| Income Tax Expense | 0 | 0 | 0 | 185K | 0 |
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Net Margin | -3468.1% | -2843.3% | — | -1306.4% | -677.6% |
| EPS (Basic) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| EPS (Diluted) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| Weighted Avg Shares | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
| Weighted Avg Shares (Diluted) | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.